Consent to Participate as a Donor of Peripheral Blood Mononuclear Cells for Use in Developing Immune Therapies — Normal Volunteers May 5, 2022 By Jesse Bufkin
A Phase 1, Open-label, Dose-Ranging Study to Evaluate the Pharmacokinetics and Safety of Azacitidine Administered Subcutaneously (SC) and as Different Oral Formulations in Subjects with Myelodysplastic Syndrome (MDS), AML, Lymphoma, and Multiple Myeloma May 5, 2022 By Jesse Bufkin
A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination with Gemtuzumab Ozogamicin (Mylotarg®) and 5-Azacytidine (Vidaza®) in Patients ≥50 Years of Age with Relapsed/Refractory non-APL Acute Myeloid Leukemia (AML) May 5, 2022 By Jesse Bufkin
Conditioning with treosulfan, fludarabine and escalating doses of TBI for allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) May 5, 2022 By Jesse Bufkin
Allogeneic hematopoietic cell transplantation for patients with nonmalignant inherited disorders using a Treosulfan based preparative regimen May 5, 2022 By Jesse Bufkin
A Phase I Safety and Efficacy Trial of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects with HER-2/Neu (HER2) Overexpressing Tumors May 5, 2022 By Jesse Bufkin
NEXT-PREP: Novel Exploration of Therapeutics for PREP. A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir disoproxil fumarate (MVC+TDF), or Tenofovir di May 5, 2022 By Jesse Bufkin
Quantitative in vivo Pharmacodynamics of Breast Cancer Endocrine Therapy Using PET Estrogen Receptor Imaging May 5, 2022 By Jesse Bufkin
